Speakers

Who should attend?

The Programme

The Workshop

The Benefits

The Venue

Media Partners

The Programme

Programme Day One Wednesday 18 February 2009
08:30		Registration
09:00	Dr. Raymond Josephsson Head Translational Imaging F. Hoffman-La Roche Ltd.	Opening remarks from the Chair
IMPROVING THE USE OF IMAGING IN DRUG DEVELOPMENT
09:10	Dr. Rainer Kneuer Research Investigator II Global Imaging Group Novartis Institutes for BioMedical Research	Optical imaging in drug development Trends in molecular imaging Imaging modalities - rationale for optical imaging in drug discovery Design, synthesis and characterization of optical imaging tracers Optical molecular imaging "Toolbox" - selected applications Translation of optical imaging tools to the clinical arena
09:40	Wim Bleeker MD PhD Director Translational Res & Pharmacology Genmab B.V.	Optical imaging strategies for tumour xenograft models Suitability of in vivo optical imaging for studying small animal tumour models Presenting case studies on the evaluation of monoclonal antibodies targeting haematological and solid tumours Comparing with traditional techniques as measuring tumour growth in subcutaneous models and survival analysis
10:10	Dr. Daniel Zicha Head of Light Microscopy Cancer Research UK London Research Institute	Functional imaging of metastatic cells Quantitative light microscopy in tissue culture Identification of a novel metastasis suppressor 4.1B Functional role of 4.1B in motility and cancer invasion
10:40		Morning refreshments
11:10	Syed Mahmood Associate Medical Director, Clinical Imaging Physician Novartis Pharmaceuticals Corporation	The role of molecular imaging in oncology – targeting the hallmarks of cancer Reviewing the new paradigm shift from pure anatomical imaging to functional imaging techniques Discussing differences between molecular imaging and routinely performed imaging of radiology departments Examining major progress areas in molecular imaging strategies to target the “cancer cell biology” Discussing utilization of molecular imaging modalities in current and emerging applications of molecular imaging
11:40	Dr. Anat Shirvan EVP R&D APOSENSE	Clinical imaging of Apotosis by 18F-ML-10, a novel small-molecule PET tracer - a tool for accelerating drug development Pre clinical imaging of Apoptosis with 18F-ML-10 Clinical imaging of physiological and pathological apoptosis in humans by 18F-ML-10 Monitoring tumour response to radiotherapy using 18F-ML-10: clinical study results
UTILISING IMAGING BIOMARKERS
12:10	Prof. Wiro Niessen Professor of Biomedical Image Analysis Biomedical Imaging Group Rotterdam Erasmus MC University Medical Rotterdam / Applied Sciences Delft University of Technology	Development and validation of quantitative imaging biomarkers in cardiovascular and neurodegenerative disease Quantitative image analysis Image-based quantification of atherosclerotic plaque Morphological and functional biomarkers of neurodegenerative disease
12:40		Lunch
13:40	Dr. Sidath Katugampola Principal Scientist Target Occupancy and Translational Imaging Experimental Biological Sciences Pfizer UK	Preclinical occupancy - a target biomarker and its application in drug discovery Preclinical methodologies for determining target occupancy Building occupancy, exposure and efficacy relationships in drug discovery projects Using preclinical occupancy to build confidence for translational imaging
14:10	Dr. rer. nat. Katarina Wolf Microscopical Imaging of the Cell, Department of Cell Biology NCMLS Radboud University Nijmegen Medical Centre	New clinical in vitro and in vivo models to image molecular markers of invasion Imaging cancer invasion and compensatory mechanisms after drug treatment Imaging biomarker activity and action (i.e. protease activity vs. substrate degradation) Bridging in vitro and in vivo pre-clinical imaging – and related challenges
DISCUSSING NUCLEAR AND MRI APPLICATIONS
14:40	Prof. Karl Herholz Director, Wolfson Molecular Imaging Centre University of Manchester	Current status of PET in clinical dementia research Imaging techniques for early specific diagnosis of dementia subtypes Longitudinal studies of the pathophysiology of progression Therapeutic studies to relate mechanisms of action and treatment efficacy
15:10	Prof. Alan Perkins Professor of Medical Physics, School of Clinical Science UNIVERSITY OF NOTTINGHAM and Honorary Secretary of the BRITISH NUCLEAR MEDICINE SOCIETY	Nuclear medicine imaging in drug delivery Discussing the role of gamma scintigraphy Outlining the scope of studies Validating radio labeling Examining oral dose forms and IV drug targeting
15:40		Afternoon refreshments
16:10	Corwin van Heteren Business Director MILabs	Ultra-high resolution molecular imaging with Single Photon Emission Computed Tomography Technology for 0.3 mm resolution SPECT in rodents Combining small animal SPECT with other modalities Quantitative SPECT imaging Application of ultra-high resolution SPECT in cardiology, neuroscience and oncology
16:40	Stella Ahier Radiographer Manager Clinical Imaging Sciences Centre, Brighton and Sussex Medical School, UNIVERSITY OF SUSSEX	Technical consideration for the use of FDG PET in drug trials Reviewing research FDG PETCT versus clinical Benefits and limitations of quantification Discussing combining perfusion CT and FDG PETCT
17:10	Dr Iman El-Hariry MD, PhD Group Director Oncology MDC Europe GlaxoSmithKline R&D	Role of PET imaging in oncology Allocating the value of PET in oncology Integrating in rational drug design Outlining limitations and advantages Discussing current and future challenges Presenting examples with a case study
17:40		Closing remarks from the Chair
17:50		Close of Day One

Programme Day Two Thursday 19 February 2009

08:30

Registration

09:00

Stella Ahier
Radiographer Manager
Clinical Imaging Sciences Centre
Brighton and Sussex Medical School
University of Sussex

Opening remarks from the Chair

09:10

Roundtable morning

Delegates will be able to attend three one-hour roundtable discussion groups from a selection of key topics. Each session will be chaired by an industry expert who will facilitate an exchange of opinions, essential experiences and learning related to a current aspect of molecular imaging in drug development.


1	Effective use of biomarkers in oncology drug development Dr Iman El-Hariry MD, PhD, Group Director Oncology MDC Europe GlaxoSmithKline R&D	2	The development and validation of quantitative imaging biomarkers Prof. Wiro Niessen Professor of Biomedical Image Analysis Biomedical Imaging Group Rotterdam Erasmus MC University Medical Rotterdam / Applied Sciences Delft University of Technology	3	Comparing imaging systems in regards to effectiveness, amount of data, comparability, translatability and cost-effectiveness Dr. rer. nat. Katarina Wolf Microscopical Imaging of the Cell Department of Cell Biology NCMLS Radboud University Nijmegen Medical Centre

4	Discussing pros and cons of imaging technologies Prof. Alan Perkins Professor of Medical Physics School of Clinical Sciences University of Nottingham and Honorary Secretary of the British Nuclear Medicine Society	5	Data Management in molecular imaging Omer Casher Manager Medical Imaging IT GSK Clinical Imaging Centre

12:30

Lunch